Antibody Cocktail Reduces Chance of Developing COVID
Two long-acting antibodies — tixagevimab mixed with cilgavimab — reduced the risk of developing symptomatic COVID by 77% in a phase 3 trial of adults at high risk of contracting the virus.
United States Mayo Clinic In Rochester United Kingdom Raymund Razonable Medscape Coronavirus Resource Center Coronavirus Resource
Source: medscape.com